Results 141 to 150 of about 25,087 (209)

Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population. [PDF]

Future Oncol
Roth JA, D'Amico PG, Cappelleri JC, Donckels EA, Yu A, Okunev I, Petrilla A, Purcell S, Ma J, Russell A.   +9 more
europepmc   +1 more source

Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel. [PDF]

Front Med (Lausanne)
Alotaibi G, Aleem A, Absi A, Alaskar AS, Alfraih F, Alhejazi A, Almasari A, Alzahrani MF, Motabi I, El Fakih R.   +9 more
europepmc   +1 more source

Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia. [PDF]

Hemasphere
Brander DM, Roberts AW, Kipps TJ, Ma S, Anderson MA, Boyer M, Blombery P, Popovic R, Roser J, Liu Z, Chyla B, Seymour JF.   +11 more
europepmc   +1 more source

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy. [PDF]

Hemasphere
Vänttinen I, Saad J, Ruokoranta T, Kytölä S, Qin G, Tercan B, Ettala P, Partanen A, Pyörälä M, Rimpiläinen J, Siitonen T, Manninen M, Valk PJM, Huls G, Thorsson V, Heckman CA, Kontro M, Kuusanmäki H.   +17 more
europepmc   +1 more source

Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]

, 2019
Lenihan, Daniel J, Stockerl-Goldstein, Keith E, Zhang, Kathleen W   +2 more
core   +1 more source

Mel Greaves: Cancer through the Lens of Evolution [PDF]

, 2016
RAMACHANDRAN, P
core   +2 more sources

Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study. [PDF]

Lancet Reg Health Southeast Asia
Sidhu J, Chakraborty A, Das P, Steffen FD, Kundu S, Basu S, Tarafdar B, Dey T, Kar A, Biswas M, Das A, Sivadasan N, Dasgupta P, Ghara N, Bornhauser B, Bourquin JP, Krishnan S, Saha V.   +17 more
europepmc   +1 more source

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer. [PDF]

Cancer Chemother Pharmacol
Perimbeti S, Jamroze A, Gopalakrishnan D, Jain R, Jiang C, Holleran JL, Parise RA, Bies R, Quinn D, Attwood K, Liu X, Green K, Kirk JS, Beumer JH, Tang DG, Chatta G.   +15 more
europepmc   +1 more source

The role of m6A RNA methyltransferase METTL3 in drug resistance mechanisms in acute myeloid leukemia. [PDF]

Blood Res
Prajapati S, Jyotishi C, Patel M, Gupta R.   +3 more
europepmc   +1 more source

Triplet regimens for frontline treatment of CLL-Great company or just a crowd? [PDF]

Hemasphere
McKeague S, Seymour JF.
europepmc   +1 more source